Key result
PPARgamma2 Ala12 variant linked to ~19% lower T2D risk, particularly at lower BMI and in Asia.
Why the study?
Conflicting results have been reported regarding the role of the PPARgamma2 Pro12Ala polymorphism in type 2 diabetes risk, suggesting genetic heterogeneity.
Does the PPARgamma2 Ala12 variant reduce the risk of type 2 diabetes?
Population
42,910 subjects from 41 published and 2 unpublished studies
Comparison
PPARgamma2 Ala12 carriers vs non-carriers
Design
Meta-analysis
Authors
Loading...
PPARgamma2 Ala12 should not guide T2D risk assessment; leaves open BMI-modulated genetic effects for prospective validation.
Meta-Analysis (n=42,910)
Yes
Does the PPARgamma2 Ala12 variant reduce the risk of type 2 diabetes?
Effect estimate: 19% risk reduction
The PPARgamma2 Ala12 variant is associated with a reduced risk of type 2 diabetes, though the protective effect is highly heterogeneous and modulated by BMI and geographic region.
Ludovico et al. (2007) conducted a meta-analysis in Type 2 diabetes (T2D) (n=42,910). PPARgamma2 Pro12Ala polymorphism (Ala12 variant) vs. Non-carriers was evaluated on Type 2 diabetes risk (19% risk reduction). Carriage of the PPARgamma2 Ala12 variant was associated with a 19% reduction in type 2 diabetes risk, with the protective effect being greater in populations with lower BMI and in Asia.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: